公开(公告)号：US5767108A

公开(公告)日：1998-06-16

申请号：US518147

申请日：1995-08-22

申请人： Patrick Cahalan ,  Theo Lindhout ,  Benedict Fouache ,  Michel Verhoeven ,  Linda Cahalan ,  Marc Hendriks ,  Ron Blezer

发明人： Patrick Cahalan ,  Theo Lindhout ,  Benedict Fouache ,  Michel Verhoeven ,  Linda Cahalan ,  Marc Hendriks ,  Ron Blezer

IPC分类号： A61L33/00 ,  A61L33/12 ,  A61K31/70

CPC分类号： A61L33/0029 ,  A61L33/128 ,  Y10S514/802 ,  Y10S514/822

摘要： A method of treating a patient with a medical device having immobilized heparin on a blood-contacting surface in which the covalently attached heparinized surface is provided with an adsorbed protein which may be activated by the immobilized heparin to block the coagulation of fibrinogen. Antithrombin III is the preferred adsorbed protein. The adsorbed protein is maintained on the immobilized heparin surface until the medical device is placed into contact with the patient's blood. When in contact with the patient's blood, the adsorbed protein will prevent initial thrombin formation at the biomaterial-blood interface. The preadsorption of ATIII is accomplished under conditions advantageous to maximum heparin/ATIII binding. When the preadsorbed surface comes in contact with whole blood, the maximum advantage of prophlactic properties of ATIII/heparin are obtained.

摘要翻译： 在患有共价连接的肝素化表面的血液接触表面上用具有固定化肝素的医疗装置治疗患者的方法，所述吸附蛋白可被固定化肝素激活以阻断纤维蛋白原的凝结。 抗凝血酶III是优选的吸附蛋白。 吸附的蛋白质保持在固定化的肝素表面上，直到医疗装置与患者的血液接触。 当与患者的血液接触时，吸附的蛋白质将阻止在生物材料 - 血液界面处的初始凝血酶形成。 ATIII的预吸附在有利于最大肝素/ ATIII结合的条件下完成。 当预吸附的表面与全血接触时，获得了ATIII /肝素的前体特性的最大优点。